FI895516A0 - Medel foer att hindra foerstoering av benmaerg. - Google Patents

Medel foer att hindra foerstoering av benmaerg.

Info

Publication number
FI895516A0
FI895516A0 FI895516A FI895516A FI895516A0 FI 895516 A0 FI895516 A0 FI 895516A0 FI 895516 A FI895516 A FI 895516A FI 895516 A FI895516 A FI 895516A FI 895516 A0 FI895516 A0 FI 895516A0
Authority
FI
Finland
Prior art keywords
foerstoering
benmaerg
foer att
medel foer
hindra
Prior art date
Application number
FI895516A
Other languages
English (en)
Inventor
Jaime Simon
Joseph R Garlich
David A Wilson
Kenneth Mcmillan
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of FI895516A0 publication Critical patent/FI895516A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI895516A 1988-12-19 1989-11-20 Medel foer att hindra foerstoering av benmaerg. FI895516A0 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/284,875 US4882142A (en) 1988-12-19 1988-12-19 Bone marrow suppressing agents

Publications (1)

Publication Number Publication Date
FI895516A0 true FI895516A0 (fi) 1989-11-20

Family

ID=23091850

Family Applications (1)

Application Number Title Priority Date Filing Date
FI895516A FI895516A0 (fi) 1988-12-19 1989-11-20 Medel foer att hindra foerstoering av benmaerg.

Country Status (17)

Country Link
US (1) US4882142A (fi)
EP (1) EP0374501B1 (fi)
JP (1) JP2795934B2 (fi)
KR (1) KR0142907B1 (fi)
AT (1) ATE92339T1 (fi)
AU (1) AU625644B2 (fi)
CA (1) CA2003326C (fi)
DE (1) DE68908125T2 (fi)
DK (1) DK175607B1 (fi)
FI (1) FI895516A0 (fi)
HK (1) HK152395A (fi)
IE (1) IE69049B1 (fi)
IL (1) IL92373A (fi)
NZ (1) NZ231474A (fi)
PH (1) PH26086A (fi)
PT (1) PT92362B (fi)
ZA (1) ZA898866B (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064633A (en) * 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
US5059412A (en) * 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
US4976950A (en) * 1988-12-19 1990-12-11 The Dow Chemical Company Bone marrow suppressing agents
WO1991016075A1 (en) * 1990-04-20 1991-10-31 Australian Nuclear Science & Technology Organisation Bone marrow treatments
MC2260A1 (fr) * 1990-06-18 1993-04-26 Dow Chemical Co Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation
US5133956A (en) * 1991-05-30 1992-07-28 The Dow Chemical Company Radiolabeled metal-binding protein for the treatment of arthritis
US5320829A (en) * 1991-12-10 1994-06-14 The Dow Chemical Company Oral compositions for inhibiting plaque formation
US6770304B2 (en) * 1997-11-10 2004-08-03 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
EP1044025A2 (en) * 1998-01-06 2000-10-18 The University of Virginia Patent Foundation Nuclear scintigraphic assessment of mucosal function
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
AU5871000A (en) * 1999-06-11 2001-01-02 Paul G. Abrams High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US6794371B1 (en) * 1999-10-18 2004-09-21 The Dow Chemical Company Aminoalkylenephosphonates for treatment of bone disorders
US6565828B2 (en) * 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US6440389B1 (en) 2000-07-19 2002-08-27 The General Hospital Corporation Fluorescent agents for real-time measurement of organ function
WO2002062398A2 (en) 2001-01-08 2002-08-15 Neorx Corporation Radioactively labelled conjugates of phosphonates
US6776977B2 (en) * 2001-01-09 2004-08-17 Bristol-Myers Squibb Pharma Company Polypodal chelants for metallopharmaceuticals
US20030215391A1 (en) * 2001-07-19 2003-11-20 Carlos Rabito Fluorescent agents for real-time measurement of organ function
AU2002364552A1 (en) 2001-12-13 2003-06-30 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
US20030228256A1 (en) * 2002-06-11 2003-12-11 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
EP1572247A1 (en) * 2002-12-10 2005-09-14 University Of Miami Radioablation of hemolymphopoietic cell populations
WO2007126730A1 (en) * 2006-03-29 2007-11-08 Isotherapeautics Group Llc Radionuclide therapy for urinary bladder cancer
PT3054996T (pt) * 2013-10-07 2023-08-01 Igl Pharma Inc Processo para preparar agentes ósseos terapêuticos de alta pureza
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
EP3302496B1 (en) * 2015-05-25 2021-01-06 IGL Pharma, Inc. Dotmp kit formulations for radioisotopes
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508625A (en) * 1982-10-18 1985-04-02 Graham Marshall D Magnetic separation using chelated magnetic ions
ZA852799B (en) * 1984-06-04 1986-12-30 Dow Chemical Co Organic amine phosphonic acid complexes for the treatment of calcific tumors
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents

Also Published As

Publication number Publication date
HK152395A (en) 1995-09-29
IE893714L (en) 1990-06-19
US4882142A (en) 1989-11-21
PT92362B (pt) 1995-09-12
NZ231474A (en) 1992-06-25
IE69049B1 (en) 1996-08-07
DK175607B1 (da) 2004-12-27
JPH02237936A (ja) 1990-09-20
PH26086A (en) 1992-02-06
DE68908125D1 (de) 1993-09-09
EP0374501B1 (en) 1993-08-04
EP0374501A1 (en) 1990-06-27
DK582789A (da) 1990-06-20
ZA898866B (en) 1991-07-31
DE68908125T2 (de) 1994-03-03
IL92373A (en) 1995-08-31
CA2003326C (en) 1999-01-19
KR900009080A (ko) 1990-07-02
DK582789D0 (da) 1989-11-20
PT92362A (pt) 1990-06-29
JP2795934B2 (ja) 1998-09-10
ATE92339T1 (de) 1993-08-15
KR0142907B1 (ko) 1998-07-15
AU625644B2 (en) 1992-07-16
AU4544089A (en) 1990-06-21
CA2003326A1 (en) 1990-06-19

Similar Documents

Publication Publication Date Title
FI895516A0 (fi) Medel foer att hindra foerstoering av benmaerg.
DE3874250T2 (de) Anaesthesiemittel enthaltende kaugummi-zusammensetzungen.
IE791203L (en) Radioactive scanning agents with hydroquinone as stabilizer
CA2005880A1 (en) Macrocyclic aminophosphonic acid complexes, their preparation formulations and use
ATE212846T1 (de) Bisphosphonat und anti-resorption agentien, enthaltende zusammensetzungen zur hemmung der knochenschwund
GB8826066D0 (en) New use of 11 28-dioxa-4-azatricyclo(22 3 1 0 4.9)octacos-18-ene derivatives & pharmaceutical compositions
NZ235499A (en) Radiolabelled hirudin analogues, pharmaceutical compositions and in vitro and in vivo detection of thrombin
GB2219304B (en) Powdered carpet deodorizer compositions
DE3370935D1 (en) Stable radiographic imaging agents
DE69110554T2 (de) Radiopharmazeutische Zusammensetzungen, Verabreichungsmethode und Verfahren zur Herstellung derselben.
IL86901A0 (en) 6,7-dihydropyrazolo-(1,5-a)(1,3,5)triazine-2-sulphonamide derivatives and herbicidal compositions containing the same
GB8811763D0 (en) Compositions containing glyphosate simazine & diuron
DE3862843D1 (de) Kationische komplexe des technetiums-99m.
IL88742A0 (en) Virus inhibiting compositions
NZ219060A (en) Fungicidal compositions containing dithianon (5,10-dihydro-5,10-dioxonaphtho(2,3-b)-1,4-dithiin-2,3- dicarbonitrile)
NZ224889A (en) Substituted 1,3-dithane derivatives and pesticidal compositions
NZ231636A (en) Anticoagulant peptides analogus to hirudins' active site
HUT47792A (en) Herbicide compositions containing 2,6-substituted-pyridine-carboxylic acid derivatives as active components and process for producing the active components
KR880013576A (ko) 골수억제 조성물 및 이의 용도
IL71905A0 (en) Bicyclo(3.2.1)octanecarboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
NZ225791A (en) Substituted tetrazole derivatives and pharmaceutical compositions
ZA893517B (en) Peptide-drug compositions containing alpha-aminoboronic acid derivatives
GB2171920B (en) Mechanical horse for children's play
EP0431146A4 (en) Radionuclide metal chelates for the radiolabeling of proteins
PH25927A (en) 3,4-dihydroisoquinolinylacetic acid derivatives and pharmaceutical composition containing these compounds

Legal Events

Date Code Title Description
FD Application lapsed

Owner name: THE DOW CHEMICAL COMPANY